Medicine

HIV avoidance via PrEP in cisgender women

.RESEARCH STUDY FEATURE.06 August 2024.

A large randomized regulated trial with cisgender women highlights the challenges of faithfulness to a daily dental preexposure prophylaxis regiment and illustrates that twice-yearly treatment of lenacapavir may maintain helpful HIV deterrence amounts over 6 months.